Alvocidib

Acute Myeloid Leukemia

M.D. Anderson Cancer CenterSmall moleculePhase 2Dormant

BB

70/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 59/ 100
Competitive Position: 89/ 100

Competitive context

588 Active assets in the Acute Myeloid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Gemtuzumab M.D. Anderson Cancer Center	Phase 4	A
AMSACRINE University Hospital, Toulouse	Phase 4	BBB
Posaconazole AstraZeneca	Phase 4	BBB
(+)-VINCRISTINE Janssen Research & Development, LLC	Phase 3	BBB
Aclacinomycin Chinese PLA General Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

Alvocidib is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

BB

Indicative · Phase 2

71 / 100

acute monocytic leukemiaDormant

BB

Indicative · Phase 2

67 / 100

adult acute monocytic leukemiaDormant

BB

Indicative · Phase 2

67 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.